|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
US5204244A
(en)
|
1987-10-27 |
1993-04-20 |
Oncogen |
Production of chimeric antibodies by homologous recombination
|
|
US5202238A
(en)
|
1987-10-27 |
1993-04-13 |
Oncogen |
Production of chimeric antibodies by homologous recombination
|
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5961974A
(en)
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
|
|
US5981724A
(en)
|
1991-10-25 |
1999-11-09 |
Immunex Corporation |
DNA encoding CD40 ligand, a cytokine that binds CD40
|
|
US7405270B2
(en)
|
1991-10-25 |
2008-07-29 |
Immunex Corporation |
CD40-Ligand lacking native-pattern glycosylation
|
|
US5866114A
(en)
|
1992-06-09 |
1999-02-02 |
Chiron Corporation |
Crystallization of M-CSFα
|
|
DE69303494T2
(de)
|
1992-11-13 |
1997-01-16 |
Idec Pharma Corp |
Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
UA40577C2
(uk)
|
1993-08-02 |
2001-08-15 |
Мерк Патент Гмбх |
Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
|
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US6239116B1
(en)
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
|
JPH0967400A
(ja)
|
1995-08-31 |
1997-03-11 |
Toray Ind Inc |
モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用
|
|
CA2282410A1
(en)
|
1997-03-03 |
1998-10-01 |
Bristol-Myers Squibb Company |
Monoclonal antibodies to human cd6
|
|
WO1998052976A1
(en)
|
1997-05-21 |
1998-11-26 |
Biovation Limited |
Method for the production of non-immunogenic proteins
|
|
WO1999017798A1
(en)
|
1997-10-02 |
1999-04-15 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
|
|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
|
DE19935756A1
(de)
|
1999-07-27 |
2001-02-08 |
Mologen Forschungs Entwicklung |
Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
|
|
DE50002293D1
(de)
|
1999-10-28 |
2003-06-26 |
Hofbauer Reinhold |
Verwendung von csf-1-inhibitoren
|
|
ES2274823T3
(es)
|
1999-12-29 |
2007-06-01 |
Immunogen, Inc. |
Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica.
|
|
US7108852B2
(en)
|
2000-03-20 |
2006-09-19 |
Warner-Lambert Company Llc |
Methods of treating inflammation using antibodies to M-CSF
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
CN1787837A
(zh)
|
2002-11-15 |
2006-06-14 |
希龙公司 |
防止和治疗癌转移以及与癌转移相关的骨质损失的方法
|
|
GB0325836D0
(en)
|
2003-11-05 |
2003-12-10 |
Celltech R&D Ltd |
Biological products
|
|
EP3434275A1
(en)
|
2003-11-06 |
2019-01-30 |
Seattle Genetics, Inc. |
Assay for cancer cells based on the use of auristatin conjugates with antibodies
|
|
CA2574654C
(en)
|
2004-07-22 |
2014-02-18 |
Five Prime Therapeutics, Inc. |
Compositions and methods of use for mgd-csf in disease treatment
|
|
AR054428A1
(es)
|
2005-03-08 |
2007-06-27 |
Pharmacia & Upjohn Co Llc |
Composiciones de anticuerpos anti factor estimulante de colonia de macrofagos (anti-m-csf) que tienen menores niveles de endotoxina
|
|
EP1885399B1
(en)
|
2005-05-26 |
2010-10-20 |
Seattle Genetics, Inc. |
Humanized anti-cd40 antibodies and their methods of use
|
|
KR101510065B1
(ko)
|
2005-06-08 |
2015-04-07 |
다나-파버 캔서 인스티튜트 인크. |
예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
|
|
AU2006329944A1
(en)
|
2005-12-09 |
2007-07-05 |
Seattle Genetics, Inc. |
Methods of using CD40 binding agents
|
|
EP1984024A2
(en)
|
2006-01-05 |
2008-10-29 |
Novartis AG |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
|
US20070280935A1
(en)
|
2006-04-07 |
2007-12-06 |
Bernd Bohrmann |
Antibody that recognizes phosphorylated peptides
|
|
AU2007333146A1
(en)
|
2006-12-12 |
2008-06-19 |
Idera Pharmaceuticals, Inc. |
Synthetic agonists of TLR9
|
|
CA2947292C
(en)
|
2006-12-27 |
2019-07-23 |
Emory University |
Compositions and methods for the treatment of infections and tumors
|
|
EP2132227A1
(en)
|
2007-03-30 |
2009-12-16 |
F. Hoffmann-Roche AG |
Composition of labeled and non-labeled monoclonal antibodies
|
|
AU2008262384B9
(en)
|
2007-06-05 |
2014-11-27 |
Yale University |
Inhibitors of receptor tyrosine kinases and methods of use thereof
|
|
RS56743B1
(sr)
|
2007-08-21 |
2018-03-30 |
Amgen Inc |
Humani c-fms antigen vezujući proteini
|
|
CN101970496B
(zh)
|
2008-03-14 |
2014-04-16 |
特朗斯吉有限公司 |
针对csf-1r的抗体
|
|
US8470977B2
(en)
|
2008-03-14 |
2013-06-25 |
Transgene S.A. |
Antibody against the CSF-1R
|
|
CN102046660A
(zh)
|
2008-03-26 |
2011-05-04 |
塞勒兰特治疗公司 |
骨髓性血液学增殖性病症相关的免疫球蛋白和/或toll样受体蛋白及其用途
|
|
EP4209510B1
(en)
|
2008-12-09 |
2024-01-31 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
RU2011135993A
(ru)
|
2009-01-30 |
2013-03-10 |
Идера Фармасьютикалз, Инк. |
Новые синтетические агонисты tlr9
|
|
EP2993188B1
(en)
|
2009-04-20 |
2020-08-19 |
Kyowa Kirin Co., Ltd. |
Anti cd40 antibody containing igg2 having three amino acid mutations introduced therein
|
|
NO2504364T3
(enExample)
|
2009-11-24 |
2018-01-06 |
|
|
|
EP2949670B1
(en)
|
2009-12-10 |
2019-02-27 |
F. Hoffmann-La Roche AG |
Antibodies binding preferentially human csf1r extracellular domain 4 and their use
|
|
JP5989547B2
(ja)
|
2010-03-05 |
2016-09-07 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ヒトｃｓｆ−１ｒに対する抗体及びその使用
|
|
KR101656548B1
(ko)
|
2010-03-05 |
2016-09-09 |
에프. 호프만-라 로슈 아게 |
인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
|
|
AR080794A1
(es)
|
2010-03-26 |
2012-05-09 |
Hoffmann La Roche |
Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
|
|
AR080698A1
(es)
*
|
2010-04-01 |
2012-05-02 |
Imclone Llc |
Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
|
|
SMT201900074T1
(it)
|
2010-05-04 |
2019-02-28 |
Five Prime Therapeutics Inc |
Anticorpi che legano csf1r
|
|
JP5813778B2
(ja)
|
2010-11-19 |
2015-11-17 |
イデラ ファーマシューティカルズ インコーポレイテッドＩｄｅｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
トール様受容体に基づく免疫反応を調節するための免疫調節オリゴヌクレオチド（ｉｒｏ）化合物
|
|
GB201021867D0
(en)
|
2010-12-23 |
2011-02-02 |
Mologen Ag |
Non-coding immunomodulatory DNA construct
|
|
ES2692268T5
(en)
|
2011-03-29 |
2025-02-26 |
Roche Glycart Ag |
Antibody fc variants
|
|
FR2975600B1
(fr)
|
2011-05-24 |
2013-07-05 |
Assist Publ Hopitaux De Paris |
Agents pour le traitement de tumeurs
|
|
CA2841013C
(en)
|
2011-07-18 |
2020-04-21 |
Morphosys Ag |
Use of c-fms antagonists
|
|
EP2739358B1
(en)
|
2011-08-01 |
2018-11-28 |
F.Hoffmann-La Roche Ag |
Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
|
AU2012324847B2
(en)
|
2011-10-21 |
2017-01-12 |
Transgene Sa |
Modulation of macrophage activation
|
|
US9624298B2
(en)
|
2011-11-28 |
2017-04-18 |
Merck Patent Gmbh |
Anti-PD-L1 antibodies and uses thereof
|
|
EP2791174B1
(en)
|
2011-12-15 |
2018-02-28 |
F. Hoffmann-La Roche AG |
Antibodies against human csf-1r and uses thereof
|
|
CN104093740B
(zh)
|
2012-02-06 |
2018-01-09 |
弗·哈夫曼-拉罗切有限公司 |
使用csf1r抑制剂的组合物和方法
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
US8993614B2
(en)
|
2012-03-15 |
2015-03-31 |
F. Hoffmann-La Roche Ag |
Substituted pyrrolidine-2-carboxamides
|
|
US20130302322A1
(en)
|
2012-05-11 |
2013-11-14 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
KR20150018533A
(ko)
|
2012-05-11 |
2015-02-23 |
파이브 프라임 테라퓨틱스, 인크. |
콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
|
|
CN104684582A
(zh)
|
2012-08-31 |
2015-06-03 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
|
AU2013343556B2
(en)
|
2012-11-09 |
2018-06-28 |
Transgene Sa |
Modulation of monocytes, or precursors thereof, differentiation
|
|
AR095882A1
(es)
|
2013-04-22 |
2015-11-18 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
|
|
AR097584A1
(es)
*
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
|
TWI680138B
(zh)
*
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
MX2017000546A
(es)
*
|
2014-07-15 |
2017-03-08 |
Genentech Inc |
Composiciones para el tratamiento del cancer mediante el uso de antagonistas de union al eje de pd-1 e inhibidores de mek.
|
|
KR102443258B1
(ko)
|
2014-08-12 |
2022-09-14 |
엘리게이터 바이오사이언스 에이비 |
항 cd40 항체에 의한 병용 치료제
|
|
AU2015339306B2
(en)
*
|
2014-10-29 |
2021-07-22 |
Bristol-Myers Squibb Company |
Combination therapy for cancer
|
|
EP3221360A1
(en)
*
|
2014-11-17 |
2017-09-27 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
SI3240801T1
(sl)
*
|
2014-12-31 |
2021-04-30 |
Checkmate Pharmaceuticals, Inc. |
Kombinirana imunoterapija tumorja
|
|
WO2016196935A1
(en)
*
|
2015-06-03 |
2016-12-08 |
Boston Biomedical, Inc. |
Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
|
|
JP7138094B2
(ja)
|
2016-08-25 |
2022-09-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
|
|
JP7304287B2
(ja)
*
|
2016-12-22 |
2023-07-06 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
|
|
WO2018160917A1
(en)
|
2017-03-03 |
2018-09-07 |
Janssen Biotech, Inc. |
Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer
|
|
US11078283B2
(en)
*
|
2018-01-17 |
2021-08-03 |
Apexigen, Inc. |
Anti-PD-L1 antibodies and methods of use
|
|
EP3849518B1
(en)
|
2018-09-13 |
2026-03-18 |
F. Hoffmann-La Roche AG |
Csf-1r antibody formulation
|